Agios Pharmaceuticals (AGIO) News Today $32.42 +0.60 (+1.89%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Agios Pharma (AGIO) Gets a Buy from Bank of America SecuritiesJanuary 16 at 8:13 PM | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Hold from Bank of America SecuritiesJanuary 16 at 3:11 PM | markets.businessinsider.comCrispr Therapeutics AG (CRSP) Receives a Buy from Bank of America SecuritiesJanuary 15 at 2:32 PM | markets.businessinsider.comAgios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA DecisionJanuary 14, 2025 | seekingalpha.comAgios Pharmaceuticals announces key 2025 milestones, catalysts through 2026January 13, 2025 | msn.comAgios Announces Key 2025 Milestones for Innovative Rare Disease PortfolioJanuary 13, 2025 | finance.yahoo.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5% - Should You Sell?Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5% - Should You Sell?January 10, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO)January 10, 2025 | markets.businessinsider.comAgios Pharmaceuticals announces FDA accepted sNDA for PYRUKYNDJanuary 9, 2025 | markets.businessinsider.comFDA To Decide On Agios' Request For Expanded Approval Of PYRUKYND In Thalassemia By September 7.January 9, 2025 | markets.businessinsider.comInsider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares of StockJanuary 8, 2025 | insidertrades.comAgios Pharmaceuticals (NASDAQ: AGIO) Receives FDA Approval for Update to PYRUKYND Treatment for Hemolytic Anemia in Adults with PK DeficiencyOn January 3, 2025, Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) haJanuary 8, 2025 | americanbankingnews.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 SharesAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 7, 2025 | marketbeat.comBank of America Securities downgrades Bioxcel Therapeutics (BTAI) to a SellJanuary 7, 2025 | markets.businessinsider.comAgios Pharmaceuticals price target lowered to $55 from $60 at BofAJanuary 7, 2025 | markets.businessinsider.comThe Robot Portfolio Gained 22% In 2024January 7, 2025 | forbes.comAgios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading Volume - What's Next?Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading Volume - Should You Buy?January 6, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and four have issuedJanuary 5, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)JPMorgan Chase & Co. cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,712,990 shares of the biopharmaceutical company's stock afJanuary 4, 2025 | marketbeat.comAgios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025January 3, 2025 | globenewswire.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in DecemberAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,120,000 shares, a growth of 12.0% from the November 30th total of 4,570,000 shares. Approximately 9.3% of the company's shares are short sold. Based on an average daily trading volume, of 805,900 shares, the short-interest ratio is presently 6.4 days.December 30, 2024 | marketbeat.comFranklin Resources Inc. Invests $1.50 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Franklin Resources Inc. bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm bought 36,317 shares of the biopharmaceutical company's stock, valued at approximately $1,499,000. Franklin ResouDecember 28, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Shares Down 3.9% - Time to Sell?Agios Pharmaceuticals (NASDAQ:AGIO) Trading Down 3.9% - Time to Sell?December 19, 2024 | marketbeat.comEuropean Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell DiseaseDecember 18, 2024 | finance.yahoo.comAgios Pharma Says EC Adopted Positive Decision For OMP Status Of Mitapivat In Sickle Cell DiseaseDecember 18, 2024 | markets.businessinsider.comAgios Pharmaceuticals (NASDAQ:AGIO) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday.December 18, 2024 | marketbeat.comEuropean Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell DiseaseDecember 18, 2024 | globenewswire.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2% - Should You Buy?Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2% - Here's WhyDecember 16, 2024 | marketbeat.comState Street Corp Acquires 216,484 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)State Street Corp boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,331,433 shares of the biopharmaceuticDecember 16, 2024 | marketbeat.comWhat is Zacks Research's Estimate for AGIO Q1 Earnings?Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Agios Pharmaceuticals in a report issued on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmDecember 16, 2024 | marketbeat.comFmr LLC Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fmr LLC lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 283.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,393 shares of the biopharmaceutical company's stock after buying an additiDecember 15, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.03 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional invesDecember 12, 2024 | marketbeat.comAgios Pharma’s Competitive Edge and Strong Efficacy Data Bolster Buy RatingDecember 11, 2024 | markets.businessinsider.comAgios Pharma’s Competitive Edge and Strong Efficacy Data Bolster Buy RatingDecember 11, 2024 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by BrokeragesAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buyDecember 11, 2024 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 19.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,044,154 shares of the biopharmaDecember 10, 2024 | marketbeat.comAgios Pharmaceuticals price target raised to $75 from $53 at ScotiabankDecember 9, 2024 | markets.businessinsider.comAgios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' DrugDecember 9, 2024 | msn.comAgios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatDecember 8, 2024 | markets.businessinsider.comAgios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatDecember 8, 2024 | globenewswire.comBank of America Securities Gives a Buy Rating to Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.comAre Options Traders Betting on a Big Move in Agios (AGIO) Stock?December 5, 2024 | finance.yahoo.comParkman Healthcare Partners LLC Sells 161,317 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Parkman Healthcare Partners LLC lessened its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 36.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 285,099 shares of the biopharmaceutical company's stock after selling 161,317 sDecember 4, 2024 | marketbeat.comAgios Pharmaceuticals: A Long Overdue Follow UpDecember 4, 2024 | seekingalpha.comErste Asset Management GmbH Takes $97.20 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,184,900 shares of the biopharmaceutical company's stock, valued at appDecember 1, 2024 | marketbeat.comBellevue Group AG Sells 143,633 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Bellevue Group AG decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,735,915 shares of the biopharmaceutical company'sDecember 1, 2024 | marketbeat.comCaligan Partners LP Raises Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Caligan Partners LP grew its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 12.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 579,717 shares of the biopharmaceutical company's stock after acquDecember 1, 2024 | marketbeat.comPDT Partners LLC Trims Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)PDT Partners LLC lowered its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 24.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,735 shares of the biopharmaceutical company'sDecember 1, 2024 | marketbeat.comVestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 760,000 shares of the biopharmaceutical company's stock, valued at approximateNovember 29, 2024 | marketbeat.comSummit Partners Public Asset Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Summit Partners Public Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchasNovember 29, 2024 | marketbeat.com Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Media Mentions By Week AGIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.290.64▲Average Medical News Sentiment AGIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼75▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Revolution Medicines News Lantheus News Blueprint Medicines News BridgeBio Pharma News Legend Biotech News Elanco Animal Health News Cytokinetics News Nuvalent News Grifols News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts